nach oben

Drugs

Erschienen in:

01.03.2014 | Therapy in Practice

Drug Treatment of Hypertension in Pregnancy

verfasst von: Catherine M. Brown, Vesna D. Garovic

Erschienen in: Drugs | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Hypertensive disorders represent major causes of pregnancy-related maternal mortality worldwide. Similar to the non-pregnant population, hypertension is the most common medical disorder encountered during pregnancy and is estimated to occur in about 6–8 % of pregnancies. A recent report highlighted hypertensive disorders as one of the major causes of pregnancy-related maternal deaths in the USA, accounting for 579 (12.3 %) of the 4,693 maternal deaths that occurred between 1998 and 2005. In low-income and middle-income countries, preeclampsia and its convulsive form, eclampsia, are associated with 10–15 % of direct maternal deaths. The optimal timing and choice of therapy for hypertensive pregnancy disorders involves carefully weighing the risk-versus-benefit ratio for each individual patient, with an overall goal of improving maternal and fetal outcomes. In this review, we have compared and contrasted the recommendations from different treatment guidelines and outlined some newer perspectives on management. We aim to provide a clinically oriented guide to the drug treatment of hypertension in pregnancy.

Nur mit Berechtigung zugänglich

Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183(1):S1–22.

Homer CS, Brown MA, Mangos G, Davis GK. Non-proteinuric pre-eclampsia: a novel risk indicator in women with gestational hypertension. J Hypertens. 2008;26(2):295–302. doi:10.1097/HJH.0b013e3282f1a953.CrossRefPubMed

Pettit F, Brown MA. The management of pre-eclampsia: what we think we know. Eur J Obstet Gynecol Reprod Biol. 2012;160(1):6–12. doi:10.1016/j.ejogrb.2011.09.049.CrossRefPubMed

Trogstad L, Magnus P, Stoltenberg C. Pre-eclampsia: risk factors and causal models. Best Pract Res Clin Obstet Gynaecol. 2011;25(3):329–42.CrossRefPubMed

James JL, Whitley GS, Cartwright JE. Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces. J Pathol. 2010;221(4):363–78. doi:10.1002/path.2719.CrossRefPubMed

Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology. 2009;24:147–58. doi:10.1152/physiol.00043.2008.CrossRefPubMed

Hertig A, Liere P. New markers in preeclampsia. Clin Chim Acta. 2010;411(21–22):1591–5. doi:10.1016/j.cca.2010.07.020.CrossRefPubMed

Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631–44. doi:10.1016/S0140-6736(10)60279-6.CrossRefPubMed

Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, et al. Pregenesys pre-eclampsia markers consensus meeting: what do we require from markers, risk assessment and model systems to tailor preventive strategies? Placenta. 2011;32(Suppl):S4–16. doi:10.1016/j.placenta.2010.11.022.CrossRefPubMed

10.

Brown CM, Garovic VD. Mechanisms and management of hypertension in pregnant women. Curr Hypertens Rep. 2011;13:338–46. doi:10.1007/s11906-011-0214-y.PubMedCentralCrossRefPubMed

11.

Jonsdottir LS, Arngrimsson R, Geirsson RT, Sigvaldason H, Sigfusson N. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Acta Obstet Gynecol Scand. 1995;74(10):772–6.CrossRefPubMed

12.

Smith G, Pell J, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129 290 births. Lancet. 2001;357(9273):2002–6. doi:10.1016/s0140-6736(00)05112-6.CrossRefPubMed

13.

Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ. 2003;326(7394):845. doi:10.1136/bmj.326.7394.845.CrossRefPubMed

14.

ACOG. Practice bulletin #33: diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol. 2002;99(1):159–67.CrossRef

15.

ACOG Practice Bulletin. Chronic hypertension in pregnancy. ACOG Committee on Practice Bulletins. Obstet Gynecol. 2001;98(1 suppl):177–85.

16.

Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122–31. doi:10.1097/01.AOG.0000437382.03963.88.

17.

Anderson GD, Carr DB. Effect of pregnancy on the pharmacokinetics of antihypertensive drugs. Clin Pharmacokinet. 2009;48(3):159–68. doi:10.2165/00003088-200948030-00002.CrossRefPubMed

18.

Magee LA. Drugs in pregnancy. Antihypertensives. Best Pract Res Clin Obstet Gynaecol. 2001;15(6):827–45. doi:10.1053/beog.2001.0232.CrossRefPubMed

19.

Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension. 2008;51(4):960–9. doi:10.1161/HYPERTENSIONAHA.106.075895.CrossRefPubMed

20.

James PR, Nelson-Piercy C. Management of hypertension before, during, and after pregnancy. Heart. 2004;90(12):1499–504. doi:10.1136/hrt.2004.035444.CrossRefPubMed

21.

Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet. 1982;1(8273):647–9.CrossRefPubMed

22.

Khalil A, Harrington K, Muttukrishna S, Jauniaux E. Effect of antihypertensive therapy with alpha-methyldopa on uterine artery Doppler in pregnancies with hypertensive disorders. Ultrasound Obstet Gynecol. 2010;35(6):688–94. doi:10.1002/uog.7611.PubMed

23.

Magee LA. Treating hypertension in women of child-bearing age and during pregnancy. Drug Saf. 2001;24(6):457–74.CrossRefPubMed

24.

Rothberger S, Carr D, Brateng D, Hebert M, Easterling TR. Pharmacodynamics of clonidine therapy in pregnancy: a heterogeneous maternal response impacts fetal growth. Am J Hypertens. 2010;23(11):1234–40. doi:10.1038/ajh.2010.159.CrossRefPubMed

25.

Horvath JS, Phippard A, Korda A, Henderson-Smart DJ, Child A, Tiller DJ. Clonidine hydrochloride—a safe and effective antihypertensive agent in pregnancy. Obstet Gynecol. 1985;66(5):634–8.PubMed

26.

Podymow T, August P. Antihypertensive drugs in pregnancy. Semin Nephrol. 2011;31(1):70–85. doi:10.1016/j.semnephrol.2010.10.007.CrossRefPubMed

27.

Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ. 1990;301(6752):587–9.CrossRefPubMed

28.

Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327(7421):955–60. doi:10.1136/bmj.327.7421.955.CrossRefPubMed

29.

Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007(1):CD002252. doi:10.1002/14651858.CD002252.pub2.

30.

Lowe SA, Brown MA, Dekker GA, Gatt S, McLintock CK, McMahon LP, et al. Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust N Z J Obstet Gynaecol. 2009;49(3):242–6. doi:10.1111/j.1479-828X.2009.01003.x.CrossRefPubMed

31.

Magee LA, Helewa M, Moutquin JM, von Dadelszen P. Hypertension Guideline Committee, Society of Obstetricians and Gynaecologists of Canada. Treatment of the hypertensive disorders of pregnancy. In: Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2008;30(3 Suppl 1):S24–36.

32.

Magee LA, Schick B, Donnenfeld AE, Sage SR, Conover B, Cook L, et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol. 1996;174(3):823–8.CrossRefPubMed

33.

Papatsonis DN, Lok CA, Bos JM, Geijn HP, Dekker GA. Calcium channel blockers in the management of preterm labor and hypertension in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2001;97(2):122–40.CrossRefPubMed

34.

Widerlov E, Karlman I, Storsater J. Hydralazine-induced neonatal thrombocytopenia. N Engl J Med. 1980;303(21):1235.PubMed

35.

Shoemaker CT, Meyers M. Sodium nitroprusside for control of severe hypertensive disease of pregnancy: a case report and discussion of potential toxicity. Am J Obstet Gynecol. 1984;149(2):171–3.CrossRefPubMed

36.

Sibai BM, Grossman RA, Grossman HG. Effects of diuretics on plasma volume in pregnancies with long-term hypertension. Am J Obstet Gynecol. 1984;150(7):831–5.CrossRefPubMed

37.

Jim B, Sharma S, Kebede T, Acharya A. Hypertension in pregnancy: a comprehensive update. Cardiol Rev. 2010;18(4):178–89. doi:10.1097/CRD.0b013e3181c60ca6.CrossRefPubMed

38.

Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354(23):2443–51. doi:10.1056/NEJMoa055202.CrossRefPubMed

39.

Bateman BT, Hernandez-Diaz S, Huybrechts KF, Palmsten K, Mogun H, Ecker JL, et al. Patterns of outpatient antihypertensive medication use during pregnancy in a Medicaid population. Hypertension. 2012;60(4):913–20. doi:10.1161/HYPERTENSIONAHA.112.197095.PubMedCentralCrossRefPubMed

40.

Duley L, Gulmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010;11:CD000025. doi:10.1002/14651858.CD000025.pub2.PubMed

41.

Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007(2):CD004659. doi:10.1002/14651858.CD004659.pub2.

42.

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357. doi:10.1097/01.hjh.0000431740.32696.cc.CrossRefPubMed

43.

Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. London: NICE 2010. Report No.: CG107.

44.

Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116(2 Pt 1):402–14. doi:10.1097/AOG.0b013e3181e9322a.CrossRefPubMed

45.

Bujold E. Prevention of pre-eclampsia with low-dose aspirin. J Postgrad Med. 2011;57(2):89–90. doi:10.4103/0022-3859.81857.CrossRefPubMed

46.

Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, Leveno KJ, et al. Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med. 2010;362(14):1282–91. doi:10.1056/NEJMoa0908056.PubMedCentralCrossRefPubMed

47.

Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2010(8):CD001059. doi:10.1002/14651858.CD001059.pub3.

48.

European Society of Gynecology, Association for European Paediatric C, German Society for Gender Medicine, Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(24):3147–97. doi:10.1093/eurheartj/ehr218.CrossRefPubMed

49.

Olsen SF, Osterdal ML, Salvig JD, Weber T, Tabor A, Secher NJ. Duration of pregnancy in relation to fish oil supplementation and habitual fish intake: a randomised clinical trial with fish oil. Eur J Clin Nutr. 2007;61(8):976–85. doi:10.1038/sj.ejcn.1602609.CrossRefPubMed

50.

Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130–7. doi:10.1053/j.semperi.2009.02.010.CrossRefPubMed

51.

Magee LA, von Dadelszen P, Chan S, Gafni A, Gruslin A, Helewa M et al. the control of hypertension in pregnancy study pilot trial. BJOG. 2007;114(6):770, e13–20. doi:10.1111/j.1471-0528.2007.01315.x.

52.

Wang K, Ahmad S, Cai M, Rennie J, Fujisawa T, Crispi F, et al. Dysregulation of hydrogen sulfide producing enzyme cystathionine gamma-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia. Circulation. 2013;127(25):2514–22. doi:10.1161/CIRCULATIONAHA.113.001631.CrossRefPubMed

53.

Mizutani S, Wright JW, Kobayashi H. Placental leucine aminopeptidase- and aminopeptidase A-deficient mice offer insight concerning the mechanisms underlying preterm labor and preeclampsia. J Biomed Biotechnol. 2011;2011:286947. doi:10.1155/2011/286947.PubMedCentralCrossRefPubMed

54.

George EM, Cockrell K, Aranay M, Csongradi E, Stec DE, Granger JP. Induction of heme oxygenase 1 attenuates placental ischemia-induced hypertension. Hypertension. 2011;57:941–8. doi:10.1161/hypertensionaha.111.169755.PubMedCentralCrossRefPubMed

55.

Uddin MN, Horvat D, DeMorrow S, Agunanne E, Puschett JB. Marinobufagenin is an upstream modulator of Gadd45a stress signaling in preeclampsia. Biochim Biophys Acta. 2011;1812(1):49–58. doi:10.1016/j.bbadis.2010.09.006.CrossRefPubMed

56.

McGuane J, Conrad K. GPCRs as potential therapeutic targets in preeclampsia. Drug Discov Today Dis Models. 2012;9(3):e119–27. doi:10.1016/j.ddmod.2012.05.001.PubMedCentralCrossRefPubMed

57.

Walsh SK, English FA, Crocker IP, Johns EJ, Kenny LC. Contribution of PARP to endothelial dysfunction and hypertension in a rat model of pre-eclampsia. Br J Pharmacol. 2012;166(7):2109–16. doi:10.1111/j.1476-5381.2012.01906.x.CrossRefPubMed

58.

Lowe DT. Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide. 2000;4(4):441–58. doi:10.1006/niox.2000.0296.CrossRefPubMed

59.

Motterlini R, Otterbein LE. The therapeutic potential of carbon monoxide. Nat Rev Drug Discov. 2010;9(9):728–43. doi:10.1038/nrd3228.CrossRefPubMed

60.

Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363(9426):2049–51. doi:10.1016/S0140-6736(04)16456-8.CrossRefPubMed

61.

Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(1):42–50. doi:10.1016/j.jash.2010.02.005.CrossRefPubMed

62.

Martin JN Jr, Thigpen BD, Moore RC, Rose CH, Cushman J, May W. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol. 2005;105(2):246–54. doi:10.1097/01.AOG.0000151116.84113.56.CrossRefPubMed

63.

August P. Preeclampsia: new thoughts on an ancient problem. J Clin Hypertens. 2000;2(2):115–23.

64.

Antenatal Care. Routine care for the healthy pregnant woman. London: National Institute for Health and Clinical Excellence: Guidance; 2008.

65.

O’Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European society of hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31(9):1731–68. doi:10.1097/HJH.0b013e328363e964.PubMed

66.

Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–87. doi:10.1097/HJH.0b013e3281fc975a.CrossRefPubMed

67.

Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013;7:CD001449. doi:10.1002/14651858.CD001449.pub3.PubMed

68.

Moser M, Brown CM, Rose CH, Garovic VD. Hypertension in pregnancy: is it time for a new approach to treatment? J Hypertens. 2012;30(6):1092–100. doi:10.1097/HJH.0b013e3283536319

Titel: Drug Treatment of Hypertension in Pregnancy
verfasst von: Catherine M. Brown
Vesna D. Garovic
Publikationsdatum: 01.03.2014
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 3/2014
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-014-0187-7

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Erratum to: T-Cell Trafficking and Anti-Adhesion Strategies in Inflammatory Bowel Disease: Current and Future Prospects

Umeclidinium/Vilanterol: First Global Approval

Steroid Use in Crohn’s Disease

Oxycodone/Naloxone Prolonged-Release: A Review of Its Use in the Management of Chronic Pain While Counteracting Opioid-Induced Constipation

T-Cell Trafficking and Anti-Adhesion Strategies in Inflammatory Bowel Disease: Current and Future Prospects

Erratum to: Oxycodone/Naloxone Prolonged-Release: A Review of Its Use in the Management of Chronic Pain While Counteracting Opioid-Induced Constipation